ArticleDiscover oncology2025
Construction and validation of a chemokine-related gene signature associated with prognosis, clinical significance, and immune microenvironment characteristics in cervical cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer (CC) remains a prevalent malignancy with significant mortality among women, highlighting the urgent need for reliable prognostic tools. While chemokines have emerged as pivotal regulators in tumor progression, their potential in constructing prognostic models for CC remains underexplored. This study aimed to develop a chemokine-related gene signature for outcome prediction and therapeutic guidance in CC patients.
methodsTranscriptomic data from The Cancer Genome Atlas (TCGA) cervical cancer cohort were analyzed to identify differentially expressed chemokine-related genes. Prognostic genes were screened through univariate Cox, multivariate Cox, and LASSO regression analyses, followed by the development of a risk stratification model. The model's clinical relevance was evaluated by assessing its correlations with clinicopathological features, immune profiles, pathway enrichment, and therapeutic responses. A nomogram integrating risk scores and clinical parameters was constructed for survival prediction.
resultsA nine-gene signature (CCL17, CXCL8, TNF, FOXP3, CXCL1, CCL20, ITGA5, CXCL3, CCR7) was established as an independent prognostic indicator. Kaplan-Meier analysis revealed significantly shorter overall survival (OS) and progression-free survival (PFS) in high-risk patients compared to low-risk counterparts (P < 0.05). Multivariate Cox regression confirmed the signature's independence from conventional clinical variables (P < 0.05). The nomogram demonstrated robust predictive accuracy, with 1-, 3-, and 5-year survival AUC values of 0.805, 0.729, and 0.710, respectively. Distinct immune cell infiltration patterns were observed between risk groups, with low-risk patients exhibiting enhanced potential for immunotherapy and chemotherapy responsiveness.
conclusionThis study presents a clinically applicable prognostic model based on chemokine-related genes, providing insights for risk stratification and therapeutic decision-making in CC. Further validation through multicenter cohorts and mechanistic investigations of the identified genes are warranted to advance precision oncology strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.